Differential endostatin binding to bladder, prostate and kidney tumour vessels

BJU International

Volumn 95, Issue 1, 2005, Pages 174-179

  Schmidt, Annette ^a   Sommer, Frank ^c   Reiner, Michael ^b   Klotz, Theodor ^d   Engelmann, Udo ^c   Addicks, Klaus ^b   Bloch, Wilhelm ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b Institute I for Anatomy   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Clinic of Urology   (Germany)

Author keywords

Binding; Bladder tumour; Endostatin; Endothelial cells; Kidney tumour; Prostate tumour

Indexed keywords

ANGIOGENESIS INHIBITOR; AVIDIN; COLLAGEN TYPE 18; ENDOSTATIN; EXTRAVIDIN CY3; EXTRAVIDIN GOLD; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIBODY LABELING; ARTICLE; BINDING SITE; BIOTINYLATION; BLADDER TUMOR; BRACHYTHERAPY; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CYSTECTOMY; CYTOCHEMISTRY; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; KIDNEY TUMOR; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN BINDING; TRANSURETHRAL RESECTION; TUMOR VASCULARIZATION; WESTERN BLOTTING; BENIGN TUMOR; BINDING AFFINITY; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG BINDING; DRUG MECHANISM; HISTOLOGY; IMMUNOGOLD LABELING; KIDNEY PARENCHYMA; MALIGNANT NEOPLASTIC DISEASE;

AGED; BLOTTING, WESTERN; ENDOSTATINS; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; PROSTATE; PROSTATIC NEOPLASMS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 12544253340     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05272.x     Document Type: Article

References (29)

1. O'Reilly MS, Boehm T, Shing Y et al. Endostatin. An endogenous inhibitor of angiogenesis and tumour growth. Cell 1997; 88: 277-85
2. Dhanabal M, Ramchandran R, Volk R et al. Endostatin. yeast production, mutants, and anti-tumour effect in renal cell carcinoma. Cancer Res 1999; 59: 189-97
3. Dhanabal M, Ramchandran R, Waterman MJ et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721-6
4. Chang Z, Choon A, Friedl A. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Am J Pathol 1999; 155: 71-6
5. Mundhenke C, Thomas JP, Wilding G et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 2001; 7: 3366-74
6. Herbst RS, Hess KR, Tran HT et al. Phase I study of recombinant human endostatin in patients with advanced tumors. J Clin Oncol 2002; 18: 3792-803
7. Bloch W, Huggel K, Sasaki T et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 2000; 14: 2373-6
8. Berger AC, Feldman AL, Gnant MF et al. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res 2000; 91: 26-31
9. Szary J, Szala S. Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth. Int J Cancer 2001; 91: 835-9
10. Sasaki T, Larsson H, Kreuger J et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 1999; 18: 6240-8
11. Friedl A, Chang Z, Tierney A, Rapraeger AC. Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissue. Am J Pathol 1997; 150: 1443-55
12. Schmidt A, Wenzel D, Ferring I et al. Influence of endostatin on embryonic vasculo- and angiogenesis. Dev Dyn 2004; 230: 468-80
13. Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and antiangiogenic activity. J Mol Biol 2000; 301: 1179-90
14. St Croix B, Rago C, Velculescu V et al. Genes expressed in human tumour endothelium. Science 2000; 289: 1197-202
15. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumours: implications for anti-angiogenic tumour therapies. Cancer Res 2000; 60: 1388-93
16. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-2
17. Mauceri HJ, Hanna NN, Beckett MA et al. Combined effects of angiostatin and ionising radiation in anti-tumour therapy. Nature 1998; 394: 287-91
18. Ferrara N, Chen H, Davis-Smyth T et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4: 336-40
19. Tosetti F, Ferrari N, De Flora S, Albini A. Angioprevention. Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002; 16: 2-14
20. Kumar S, Ghellal A, Li C et al. Breast carcinoma. Vascular density determined using CD105 antibody correlates with tumour prognosis. Cancer Res 1999; 59: 856-61
21. Ding I, Sun JZ, Fenton B et al. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in Mca-4 murine mammary carcinoma. Cancer Res 2001; 61: 526-31
22. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341-7
23. Karumanchi SA, Jha V, Ramchandran R et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001; 7: 811-22
24. Kim YM, Hwang S, Kim YM et al. Endostatin blocks VEGF-mediated signalling via direct interaction with KDR/ Flk-1. J Biol Chem 2002; 277: 27872-9
25. MacDonald NJ, Shivers WY, Narum DL et al. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001; 276: 25190-6
26. Messing EM, Catalona W. Urothelial tumours of the urinary tract. In Walsh PC, Retik AB, Vaughan ED, Wein AJ eds, Campbells Urology. Philadelphia: WB Saunders Co, 1998: 2329-61
27. Oefelein MG, Ignatoff JM, Clemens JQ, Watkin W, Kaul KL Clinical and molecular follow-up after radical retropubic prostatectomy. J Urol 1999; 162: 307-10
28. Moreno JG, Croce CM, Fischer R et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 1992; 52: 6110-2
29. Ablin RJ. Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br J Urol 1993; 71: 761-2